Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and schizophrenia, who receive antipsychotic treatment. Furthermore to investigate for an effect of Semaglutide compared to placebo on psychotic symptoms and quality of life in people with schizophrenia, prediabetes and overweight.
Epistemonikos ID: 67c3c90dbfcbaf02b61fb57d690ddbd199f52297
First added on: May 10, 2024